# The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

> **NCT04404049** · PHASE2 · UNKNOWN · sponsor: **UBP Greater China (Shanghai) Co., Ltd** · enrollment: 39 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **BIOLOGICAL:** UB-421(25 mg/kg) Q2W
- **BIOLOGICAL:** UB-421(25 mg/kg) Q4W

## Key facts

- **NCT ID:** NCT04404049
- **Lead sponsor:** UBP Greater China (Shanghai) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2022-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04404049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04404049, "The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04404049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*